**VZV-gE (aa 48-135)**
Varicella-zoster Virus Glycoprotein E recombinant, *E. coli*

<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>PR-1253</td>
<td>100 µg</td>
</tr>
</tbody>
</table>

For general laboratory use.

**Shipping:** shipped on gel packs

**Storage Conditions:** store at -20 °C

**Additional Storage Conditions:** avoid freeze/thaw cycles

**Shelf Life:** 12 months

**Purity:** > 95 % (SDS-PAGE)

**Form:** liquid (Supplied in 60 mM NaCl, 50 mM Tris-HCl pH 8.0, 0.25% Sarkosil, 10 mM Glutathione and 50% glycerol)

**Applications:**
Antigen in ELISA and Western blots, excellent antigen for detection of VZV with minimal specificity problems.

**Description:**
The protein contains the VZV-gE immunodominant regions, amino acids 48-135. The protein is purified by proprietary chromatographic technique.

**Background:** Varicella-zoster virus (VZV) is an extremely cell-associated alpha herpesvirus. It interacts with cell surface heparan sulfate proteoglycans during virus attachment. VZV-gE is a glycoprotein that plays an active or supportive role in VZV cell membrane fusion. VZV-gE was found to enhance the fusogenic potential of VZV gB.

**Specificity:** Immunoreactive with sera of VZV-infected individuals.

**Selected References:**
- Kenyon et al. (2002) Phosphorylation by the varicella-zoster virus ORF47 protein serine kinase determines whether endocytosed viral gE traffics to the trans-Golgi network or recycles to the cell membrane. *J. Virol.* 76:50980.